Xencor

Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.

Biotech

Earnings

News

Small Cap

Management

Markets

Analyst Ratings

Trading Ideas

General

USNA

XNCR

Xencor (NASDAQ: XNCR) shares rallied 10.5% in the last trading session to close at $21.13. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock&#39;s 19.8% gain over the past four weeks.

Xencor Surges 10.5%: Is This an Indication of Further Gains?

Penny Stocks

Intraday Update

Movers

AAOI

ALEC

ALHC

AMCX

AMRX

AMZN

ATSG

BIGC

BKNG

COLL

CYTK

DKNG

DVAX

FUBO

GDYN

INVE

IRTC

KTOS

KURA

LOPE

NTRA

OLED

OSUR

PRDO

TEAM

TRUP

TWST

U.S. stocks traded higher, with the Dow Jones gaining around 150 points on Friday. Here are some big stocks recording gains in today’s session.

Atlassian, Universal Display, Booking, Dropbox And Other Big Stocks Moving Higher On Friday

Short Ideas

Pre-Market Outlook

Hims & Hers Health, Inc. Class A Common Stock

HIMS

MLTX

PTGX

TGTX

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

Top 5 Health Care Stocks That May Collapse In February

Xencor Inc

Press Releases

Xencor Announces Pricing of $175 Million Public Offering of Common Stock

Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Xencor Announces Upcoming Change to Board of Directors

Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases

Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease

Xencor Reports Third Quarter 2024 Financial Results

Xencor to Participate at Upcoming Investor Conferences

Xencor Reports Fourth Quarter and Full Year 2024 Financial Results

Xencor Appoints Todd Simpson to Board of Directors

Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease

Akebia Therapeutics

AnaptysBio

ArriVent BioPharma

Anavex Life Sciences Corp. - Common Stock

Anavex Life Sciences

Bicara Therapeutics

Bicycle Therapeutics plc - American Depositary Shares

Bicycle Therapeutics

CareDx

Cogent Biosciences

Day One Biopharmaceuticals, Inc. - Common Stock

Day One Biopharmaceutical

Dianthus Therapeutics, Inc. - Common Stock

Dianthus Therapeutics

Geron

Gyre Therapeutics

Immunome

KalVista Pharmaceuticals, Inc. - Common Stock

KalVista Pharma

Myriad Genetics

Nurix Therapeutics

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics

Organogenesis Holdings

Praxis Precision Medicines, Inc. - Common Stock

Praxis Precision Medicine

Rocket Pharmaceuticals, Inc. - Common Stock

Rocket Pharmaceuticals

Arcus Biosciences

Replimune Group

Spyre Therapeutics

Vir Biotechnology

Zymeworks

Wells Fargo

Piper Sandler

BMO Capital

JP Morgan

RBC Capital

Comments

Xencor

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell